Biological drugs targeting the immune response in the therapy of psoriasis.
Chronic plaque psoriasis affects more than 2% of world population, has a chronic recurrent behavior, gives a heavy burden to the patients' quality of life, and hence remains a huge medical and social problem. The clinical results of conventional therapies of psoriasis are not satisfactory. According to the current knowledge of the molecular and cellular basis of psoriasis, it is defined as an immune-mediated chronic inflammatory and hyperproliferative skin disease. A new generation of biological drugs, targeting molecules and cells involved into perturbed pro-inflammatory immune response in the psoriatic skin and joints, has been recently designed and applied clinically. These biological agents are bioengineered proteins such as chimeric and humanized antibodies and fusion proteins. In particular, they comprise the antitumor necrosis factor-alpha agents etanercept, infliximab, and adalimumab, with clinical efficacy in both moderate-severe psoriasis and psoriatic arthritis, and the anti-CD11a efalizumab with selective therapeutic action exclusively in the skin. Here, we overview recent findings on the molecular pathways relevant to the inflammatory response in psoriasis and present our clinical experience with the drugs currently employed in the dermatologic manifestations, namely etanercept, infliximab, and efalizumab. The growing body of clinical data on the efficacy and safety of antipsoriasis biological drugs is reviewed as well. Particular focus is given to long-term safety concerns and feasibility of combined therapeutic protocols to ameliorate clinical results.
Pastore
Saveria
S
Laboratory of Tissue Engineering and Cutaneous Physiopathology;
Gubinelli
Emanuela
E
Leoni
Luca
L
Raskovic
Desanka
D
Korkina
Liudmila
L
Semin Arthritis Rheum. 2005 Jun;34(6):819-36
15942917
Nature. 2007 Oct 4;449(7162):564-9
17873860
Lancet. 2007 Jul 21;370(9583):263-271
17658397
J Am Acad Dermatol. 2008 Jan;58(1):125-35
17996329
Curr Opin Investig Drugs. 2002 Nov;3(11):1590-5
12476958
N Engl J Med. 2003 Nov 20;349(21):2004-13
14627785
Health Qual Life Outcomes. 2006 Sep 27;4:71
17005043
J Am Acad Dermatol. 2004 Oct;51(4):580-4
15389194
Int J Immunopathol Pharmacol. 2006 Jan-Mar;19(1):225-9
16569361
Cell. 2001 Feb 23;104(4):487-501
11239407
Expert Opin Ther Targets. 2005 Apr;9(2):225-43
15934912
Am J Pathol. 2003 Jan;162(1):203-11
12507903
Arch Dermatol. 2003 Dec;139(12):1627-32; discussion 1632
14676082
JAMA. 2003 Dec 17;290(23):3073-80
14679270
J Am Acad Dermatol. 2006 Feb;54(2):361-2
16443079
Clin Dermatol. 2007 Nov-Dec;25(6):563-7
18021893
Lancet. 2007 Jul 21;370(9583):272-284
17658398
Br J Dermatol. 2005 Jun;152(6):1304-12
15948997
Br J Dermatol. 2006 Jan;154(1):194-5
16729392
Clin Rheumatol. 2007 Jul;26(7):1134-5
17115099
Expert Opin Investig Drugs. 2000 Mar;9(3):529-42
11060693
Clin Ther. 2005 Sep;27(9):1317-28
16291408
Arch Dermatol Res. 1998 May;290(5):240-5
9681674
J Eur Acad Dermatol Venereol. 2006 Sep;20(8):988-98
16922950
J Drugs Dermatol. 2006 Jun;5(6):546-8
16774108
JAMA. 2006 May 17;295(19):2275-85
16705109
J Am Acad Dermatol. 2006 Apr;54(4 Suppl 1):S154-63
16488337
J Am Acad Dermatol. 2007 Jan;56(1):31.e1-15
17097378
Arch Dermatol. 2007 Aug;143(8):1053-7
17709665
Arch Dermatol Res. 2006 Jun;298(1):7-15
16691429
Lancet. 2005 Oct 15-21;366(9494):1367-74
16226614
Dermatol Clin. 2007 Apr;25(2):207-13, vii
17430757
Arch Dermatol. 2005 Jan;141(1):31-8
15655139
J Dtsch Dermatol Ges. 2006 Nov;4(11):947-56
17081270
Nature. 2002 Jun 20;417(6891):861-6
12075355
Br J Dermatol. 2006 Jul;155(1):170-81
16792770
Br J Dermatol. 2005 Sep;153(3):486-97
16120132
Arch Dermatol Res. 2006 Dec;298(7):329-38
17021768
Curr Drug Targets Inflamm Allergy. 2004 Jun;3(2):175-83
15180471
N Engl J Med. 2003 Nov 20;349(21):2014-22
14627786
Nature. 2007 Oct 4;449(7162):551-3
17873861
J Cell Sci. 2003 Dec 1;116(Pt 23):4695-705
14600256
Nat Clin Pract Rheumatol. 2007 Mar;3(3):156-64
17334338
N Engl J Med. 2002 Oct 10;347(15):1151-60
12374875
J Am Acad Dermatol. 2003 Jun;48(6):829-35
12789171
Genes Immun. 2007 Jan;8(1):1-12
17093502
J Am Acad Dermatol. 2004 Oct;51(4):534-42
15389187
Lancet. 2001 Jun 9;357(9271):1842-7
11410193
J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S112-9
16488321
N Engl J Med. 1979 Sep 6;301(10):555
460314
Proc Natl Acad Sci U S A. 1992 Jan 15;89(2):594-8
1731329